Paper: Glofitamab As Monotherapy and in Combination with Obinutuzumab Induces High Complete Response Rates in Patients (pts) with Multiple Relapsed or Refractory (R/R) Follicular Lymphoma (FL)

Glofitamab with obinutuzumab had a ORR of 100% and a CMR rate of 73.7% in relapsed/refractory follicular lymphoma. 79% had CRS, with no grade 3 CRS events.

Read the full article here

Related Articles